Immunogenicity and Safety of the Quadrivalent Adjuvant Subunit Influenza Vaccine in Seropositive and Seronegative Healthy People and Patients with Common Variable Immunodeficiency

Mikhail P Kostinov; Elena A Latysheva; Aristitsa M Kostinova; Nelly K Akhmatova; Tatyana V Latysheva; Anna E Vlasenko; Yulia A Dagil; Ekaterina A Khromova; Valentina B Polichshuk

doi:10.3390/vaccines8040640

Immunogenicity and Safety of the Quadrivalent Adjuvant Subunit Influenza Vaccine in Seropositive and Seronegative Healthy People and Patients with Common Variable Immunodeficiency

Vaccines (Basel). 2020 Nov 2;8(4):640. doi: 10.3390/vaccines8040640.

Authors

Mikhail P Kostinov^{1

2}, Elena A Latysheva³, Aristitsa M Kostinova³, Nelly K Akhmatova¹, Tatyana V Latysheva³, Anna E Vlasenko⁴, Yulia A Dagil³, Ekaterina A Khromova¹, Valentina B Polichshuk¹

Affiliations

¹ Federal State Budgetary Scientific Institution, I.I. Mechnikov Research Institute of Vaccines and Sera, Malyi Kazenniy pereulok, 5a, 105064 Moscow, Russia.
² Federal State Autonomous Educational Institution of Higher Education, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Trubetskaya Str., 8/2, 119991 Moscow, Russia.
³ National Research Center-Institute of Immunology Federal Medical-Biological Agency of Russia, Kashirskoe Shosse, 24, 115478 Moscow, Russia.
⁴ Novokuznetsk State Institute for Advanced Training of Physicians-Branch Campus of the Russian Medical Academy of Continuous Professional Education, Prospect Stroiteley, 5, 654005 Novokuznetsk, Russia.

Abstract

Background: Influenza prophylaxis with the use of quadrivalent vaccines (QIV) is increasingly being introduced into healthcare practice.

Methods: In total, 32 healthy adults and 6 patients with common variable immunodeficiency (CVID) received adjuvant QIV during 2018-2019 influenza season. Depending on initial antibody titers, healthy volunteers were divided into seronegative (≤1:20) and seropositive (≥1:40). To evaluate immunogenicity hemagglutination inhibition assay was used.

Results: All participants completed the study without developing serious post-vaccination reactions. Analysis of antibody titer 3 weeks after immunization in healthy participants showed that seroprotection, seroconversion levels, GMR and GMT for strains A/H1N1, A/H3N2 and B/Colorado, B/Phuket among initially seronegative and seropositive participants meet the criterion of CHMP effectiveness. CVID patients showed increase in post-vaccination antibody titer without reaching conditionally protective antibody levels.

Conclusion: Adjuvant QIV promotes formation of specific immunity to vaccine strains, regardless of antibodies' presence or absence before. In CVID patients search of new regimens should be continued.

Keywords: CVID; adjuvanted QIV; azoximer bromide; immunogenicity; influenza; seropositive/seronegative.